Michael Sinz Bristol Myers Squibb Princeton, NJ USA Biography
Biography of Michael Sinz
Michael W. Sinz, Ph.D. is Director of Metabolism and Pharmacokinetics at Bristol Myers Squibb where he manages ADmezME lead optimization in drug discovery. Dr. Sinz previously held the position of Section Director-Pharmacokinetics and Drug Metabolism for Parke-Davis/Pfizer. He received B.S. degrees in Chemistry (ACS) and Biology from the University of Wisconsin-Eau Claire and a Ph.D. in Pharmacognosy/Medicinal Chemistry from the University of Minnesota (2001). He is editor in chief of Current Drug Metabolism and associate editor of Drug Metabolism Letters. Dr. Sinz’s resume includes an extensive number of peer reviewed publications, book chapters, and external presentations both locally and internationally.
Amin Rostami-Hodjegan University of Manchester Manchester UK Biography
Biography of Amin Rostami-Hodjegan
Amin is a Professor of Systems Pharmacology at the Centre for Applied Pharmacokinetic Research (CAPKR) in the Manchester Pharmacy School at the University of Manchester. He is also the Senior Vice President of Research & Development and Chief Scientific Officer at Certara. Professor Rostami has authored/co-authored over 200 peer-reviewed full articles and serves on the Editorial Boards of several journals. He has been an invited speaker at over 170 national and international meetings and has led a number of hands on workshops in the area of in vitro-in vivo extrapolation as applied to ADME in Drug Development.
Albert P. Li In Vitro ADMET Laboratories Columbia, MD USA Biography
Biography of Albert P. Li
Dr. Li (Ph. D., Biomedical Sciences, University of Tennessee) is President and CEO of In Vitro ADMET Laboratories Inc., Columbia, MD. He was previously Senior Fellow, Monsanto Company; CSO, In Vitro Technologies; Research Professor, St. Louis University Medical School, and CEO, Phase 1 Molecular Toxicology. His research is focused on the development and application of human-based in vitro experimental models in the accurate assessment of human drug properties including metabolic fate, drug-drug interactions and drug toxicity. Dr. Li has published over 170 research articles, book chapters, and reviews, and co-edited 5 books. He holds multiple U.S and international patents.
Aleksandra Galetin University of Manchester Manchester UK Biography
Biography of Aleksandra Galetin
Dr Galetin is the Associate Professor in the Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, UK. She is the recipient of the 2012 ISSX European New Investigator Award and 2015 AAPS Meritorious Manuscript Award. Dr Galetin is appointed on the expert panels such as International Transporter Consortium Committee and AAPS Drug Transport Focus Group Steering Committee. She has published over 65 research papers in highly cited peer reviewed journals (H index 35), received more than 50 invitations to present at international meetings and supervised/mentored over 25 graduate students and postdoctoral research associates.
Nico P.E. Vermeulen Vrije Universiteit Amsterdam Amsterdam The Netherlands Biography
Biography of Nico P.E. Vermeulen
Prof. Nico P.E. Vermeulen received a doctorate degree in Chemistry (1975, University of Nijmegen, NL) and a PhD degree in Pharmacology (1980, University of Leiden, NL). He was appointed full professor in Molecular Toxicology at VU University Amsterdam (1985). Currently, he is also Director of AIMMS (Amsterdam Institute for Molecules, Medicines and Systems, at VU University). He is author of > 405 peer reviewed publications and was listed at the ISI HighlyScited.com list (e.g. 2001 and 2014). He is interested in the roles molecular and computational toxicology and drug metabolism can play in drug discovery, development and safety assessment.
Ken-ichi Fujita Showa University Tokyo Japan Biography
Biography of Ken-ichi Fujita
Dr. Fujita obtained a Ph.D. from the Graduate School of Pharmaceutical Sciences, Hokkaido University (Sapporo, Japan). Dr. Fujita also holds a Bachelor of Engineering from the School of Engineering, Tohoku University (Sendai, Japan). Currently Dr. Fujita is a Professor in the Institute of Molecular Oncology, Showa University. His present research field is clinical pharmacology in cancer pharmacotherapy. He has published more than 100 scientific publications. Dr. Fujita is currently the Associate Editor of this journal (Current Drug Metabolism).
Lee Jia is currently Distinguished Professor, “The China Recruitment Program of Global Experts” (1000-talents plan), and the founder Director, Cancer Metastasis Prevention & Alert Center, Fuzhou University, China, managing 10 cancer metastasis detection and prevention-related projects.
Prior to this position, he was the Senior Project Officer with the Developmental Therapeutics Program at the National Cancer Institute, NIH, USA (2002-2012). Before joining the NCI/NIH in 2002, he was Associate Director of Cancer Therapy and Research Center in San Antonio, TX, where he was responsible for translational research, and Associate Member of San Antonio Cancer Institute. He received his Ph.D. degree in Pharmacology from the State University of New York under the supervision of Distinguished Professor, Dr. Robert Furchgott, the 1998 Nobel Laureate.
Dr. Jia has contributed >150 original papers to high-impact journals, including Science, Nature, PNAS, Nano Today, Blood. He serves as Associate Editor of CDM and CDL. He is the Fellow of the American Association of Pharmaceutical Scientists (AAPS) and held leadership position with AAPS.
Jasminder Sahi Sanofi-Aventis Shanghai Shanghai China Biography
Biography of Jasminder Sahi
Jasminder Sahi obtained a Ph.D. degree (Pharmacognosy, 1991) from Panjab University, India and then participated in a post-doctoral program in the Department of Physiology and Biophysics, University of Illinois at Chicago. Jasminder’s research focus is on transporters and induction of drug metabolizing enzymes, using primary hepatocytes. While her initial forays into transporter research involved ion transport to understand CFTR, at Pfizer she changed her focus to xenobiotic transporters, with the goal of improving drug disposition, delivery and safety. She has worked extensively with hepatic and renal transporters as well as the very challenging blood-brain-barrier. She is an elected member of the ISSX council, a reviewer for six journals and has authored over 40 peer-reviewed publications.
Mohammad Amjad Kamal King Abdulaziz University Jeddah Saudi Arabia Biography
Biography of Mohammad Amjad Kamal
Dr. Mohammad Amjad Kamal completed three years U2000 Postdoctoral Fellowship in 2003 from the University of Sydney, School of Molecular and Microbial Biosciences. Currently Dr. Kamal is a Distinguished Adjunct Professor in the King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. He has published more than 260 scientific publications.
Dr. Kamal is serving as external examiner for PhD thesis evaluation of various universities and as an EiC/regional/editorial member/guest editor of several reputed scientific journals (mostly published by Bentham Science Publishers) on an honorable basis. Recently, he initiated efforts to establish a “Novel Global Community Educational Foundation” as well.
Editorial Board Members
U.A. Argikar Novartis Institutes for BioMedical Research Cambridge, MA USA Biography
Biography of U.A. Argikar
Upendra A. Argikar is a Senior Research Investigator at Novartis Institutes for Biomedical Research, Inc.
in Cambridge, Massachusetts, USA. He received a Ph.D. in Medicinal Chemistry from University of
Minnesota, USA. He has 15+ years of research experience in drug metabolism and pharmacokinetics. At
Novartis he has been an active member of projects spanning many disease areas. Currently, he focuses
on metabolite identification and structure elucidation of new chemical entities and clinical candidates.
Upendra has continued to be interested in conjugative metabolism by uridine diphospho-glucuronosyl
transferases, a topic on which he has co-authored research articles, reviews, and book chapters.
S.K. Balani Takeda Pharmaceuticals International Company Cambridge, MA USA Biography
Biography of S.K. Balani
Suresh Balani is in Drug Metabolism and Pharmacokinetics department at Takeda Pharmaceuticals International Co. in Cambridge, MA, currently directing drug development in Gastroenterology and Central Nervous System portfolios. He received his Ph.D. at Queen's University of Belfast, Northern Ireland, U.K., and subsequently worked at National Institutes of Health in Bethesda, MD; Merck Research Labs at West Point, PA; and DuPont Pharmaceuticals at Delaware. He has published over 100 scientific papers and abstracts, and has 10 patents. He is on the Editorial Board of Current Drug Metabolism.
K. Beaumont Pfizer Global Research and Development Kent UK Biography
Biography of K. Beaumont
Throughout 33 years in the Pharmaceutical industry, Kevin has worked extensively in the drug metabolism field. His major area of expertise is in the modulation of physicochemistry to affect drug disposition and prediction of human pharmacokinetics. He is author on over 40 peer reviewed publications.
Kevin has worked on many Discovery and Development projects throughout his career. He has been responsible for the DMPK input to at least 30 FIH studies as well as 10 Phase II compounds, including 1 marketed agent. Kevin now provides DMPK input to the Rare Disease Research Unit, based in Cambridge Massachusetts.
J. Cashman Human BioMol. Research Inst San Diego, CA USA Biography
Biography of J. Cashman
John R. Cashman. Ph.D., President, has more than 30 years experience in biomedical research. In 1997, he founded the Human BioMolecular Research Institute to do fundamental and applied research to address human diseases. Previously, he was at the Seattle Biomedical Research Institute, was Associate Director for the IGEN Research Institute and was Assistant Professor of Pharmaceutical Chemistry at UC San Francisco. He was a postdoc with Professor E.J. Corey (1982-1984). Dr. Cashman received his MS and Ph.D. in Medicinal Chemistry from the University of Kansas (1982) and bachelor degrees in chemistry and biology at the College of Creative Studies, UC Santa Barbara (1977). Dr. Cashman is the author of over 240 research articles, book chapters and patents in drug discovery and evaluation.
C. Chen National Center for Nanoscience and Technology Beijing, P. R. China Biography
Biography of C. Chen
Dr. Chen and obtained her Ph.D. degree in Biomedical engineering from Huazhong University of Science and Technology of China (1996). She is one of the earliest researchers in the field of nanosafety in China. Dr. Chen currently is a principal investigator at CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety in National Center for Nanoscience and Technology of China. She has authored/co-authored over 150 peer-reviewed papers /book chapters, has more than ten issued patents and finished one ISO standard. She has been awarded the Second Prize of the National Natural Science Awards (2012), China Outstanding Young Female Scientists Awards (2014) and the National Science Fund for Distinguished Young Scholars (2014).
Y. Daali University of Geneva Geneva Switzerland Biography
Biography of Y. Daali
Since 2002, I’m the Head of the Research Laboratory of the Clinical Pharmacology and Toxicology Service at Geneva University Hospitals. I completed my doctorate in Pharmaceutical Sciences at the School of Pharmacy of Geneva University in 2001. I joined the Clinical Pharmacology Service at Geneva University Hospitals in 2002. I’m also a senior lecturer at School of Pharmacy and at Medical school of Geneva University. My research activity is related to personalized medicine related to drug metabolism, pharmacokinetics and PBPK. I also developed several in vitro models for drugs metabolism and transport characterization and drug-drug interaction studies.
Dr. Li Di has about 20 years of experience in the pharmaceutical indus¬try including Pfizer, Wyeth and Syntex. She is currently a research fellow at Pfizer, Groton, CT. Her research interests include the areas of drug metabo¬lism, pharmacokinetics, drug-drug interactions, absorption, transporters, and blood–brain barrier. She has over 120 publications including two books and presented over 80 invited lectures. She is a recipient of the Thomas Alva Edison Patent Award, the New Jersey Association for Biomedical Research Outstanding Woman in Science Award, the Wyeth President’s Award and Peer Award for Excellence.
Dr. Huile Gao received his PhD in Pharmaceutics from School of Pharmacy, Fudan University in 2013 under the supervision of Prof. Xinguo Jiang. Then he joined the West China School of Pharmacy, Sichuan University as an Instructor in July 2013 and was promoted to an Associate Professor in July 2014. Dr. Gao’s research interests focus on the design, synthesis, characterization and evaluation of stimuli responsive nanomaterials for drug and imaging probe delivery to improve treatment and diagnosis of human diseases especially tumor and brain diseases. He has published over 80 peer-reviewed articles with an H-index of 28.
H. Glatt German Institute of Human Nutrition (DIfE) Nuthetal Germany Biography
Biography of H. Glatt
Hansruedi Glatt obtained a Ph.D. in biology from the University of Basle. He was Professor for Toxicology and Pharmacology at the University of Mainz (1987-1994), Professor for Molecular Toxicology at the University of Potsdam (1994-2013) and Head of the Department of Nutritional Toxicology at the German Institute of Human Nutrition (1994-2013). He also teaches in the Master Program in Toxicology at the Charité Berlin (since 2008) and is Senior Professor at the Federal Institute of Risk Assessment (since 2014). He has published nearly 290 articles in scientific journals and 85 book chapters.
H. Hao China Pharmaceutical University Nanjing China Biography
Biography of H. Hao
Dr. Hao obtained his Ph.D. degree in Drug Metabolism and Pharmacokinetics from China Pharmaceutical University. Currently Dr. Hao is a professor and the dean of School of Pharmacy in China Pharmaceutical University. His research mainly covers the molecular mechanisms of drug disposition and metabolic regulation guided target discovery. He has published more than 120 scientific publications and is currently an editor of this journal.
P.F. Hollenberg University of Michigan Ann Arbor, MI USA Biography
Biography of P.F. Hollenberg
Paul F. Hollenberg, Ph.D., is a Professor Emeritus of Pharmacology at the University of Michigan Medical School. He received his Ph.D. in Biological Chemistry from the University of Michigan and was a Postdoctoral Fellow at the University of Illinois. He was on the faculty at Northwestern University Medical School, Wayne State University School of Medicine (Chair of Pharmacology), and then at the University of Michigan Medical School where he was Chair for more than 20 years. He has published more than 200 peer-reviewed papers and received more that $29 million in NIH funding as a PI or Co-PI.
M. Hu University of Houston College of Pharmacy Houston, TX USA Biography
Biography of M. Hu
Ming Hu, PhD., Professor at University of Houston, is internationally known expert in phase II metabolism and drug bioavailability. His laboratory is devoted to the study of bioavailability. He is especially interested in the study of drug delivery modalities and/or mechanisms that translates into clinical utility. Dr. Hu’s lab deploys a variety of biological model systems to study ADME and PK. He has pioneered the concept of utilizing first-pass metabolism to target drugs to colon without systemic exposure or toxicity. His lab has been supported continually by NIH since 1998. He has published more than 150 papers, book and chapters.
W.G. Humphreys Bristol-Myers Squibb Princeton, NJ USA Biography
Biography of W.G. Humphreys
Griff Humphreys is currently Senior Research Fellow in the Department of Metabolism and Pharmacokinetics at Bristol-Myers Squibb. He received his graduate training in chemistry at the University of Virginia and completed post-doctoral training at the Center in Molecular Toxicology at Vanderbilt University. His interests includethe consequences of reactive metabolite formation, development of new analytical methodologies, reaction phenotyping of CYP and UGT catalyzed biotransformations, identification of endogenous probes for ADME-related protein function, predictive metabolism and toxicology models, in vitro-in vivo correlations, and strategies for candidate optimization.
J.M. Hutzler Q2 Solutions Indianapolis, IN USA Biography
Biography of J.M. Hutzler
Dr. Hutzler earned his Ph.D. in pharmaceutical sciences from West Virginia University under the direction of Dr. Timothy S. Tracy and completed a post doc at Pharmacia Corporation in Kalamazoo, Michigan with Dr. Larry Wienkers. Dr. Hutzler is currently Director of In Vitro Metabolism at Q2 Solutions Bioanalytical and ADME Labs in Indianapolis. Prior to joining Q2 Solutions, Dr. Hutzler was a drug metabolism and pharmacokinetic (DMPK) project lead at Boehringer-Ingelheim Pharmaceuticals in Connecticut, and held a similar project lead position at Pfizer Inc. in St. Louis. With over 14 years of experience in the DMPK field, Dr. Hutzler’s research has included atypical enzyme kinetics for cytochrome P450 enzymes, inhibition SAR of CYP2D6, extrapolation of in vitro data to human clearance predictions, and most recently, aldehyde oxidase. He has published more than thirty articles in peer-reviewed journals and four book chapters.
S. Ishida National Institute of Health Sciences Kawasaki Japan Biography
Biography of S. Ishida
Seiichi Ishida is Section Chief at Division of Pharmacology at
National Institute of Health Sciences. He received his PhD in Pharmaceutical Science from
the University of Tokyo, Japan in 1993, and conducted postdoctoral studies at The Cancer
Institute (Tokyo) and at Howard Hughes Medical Institute at Duke University Medical
Centre. His research focuses primarily on the development of in vitro cell assay platform
for the evaluation of drug metabolism and drug induced liver injury and their application to
the regulatory science field.
M. Kajbaf GlaxoSmithKline S.p.A., Fleming Verona Italy Biography
Biography of M. Kajbaf
Dr Mahmud Kajbaf holds a Ph.D. from the University of London, King’s College, Biopharmacy Department in the area of drug metabolism and MSc from Aston University, Birmingham.
Currently Dr Kajbaf is Senior Scientist at Aptuit. He has received several awards and honors, such as: Aptuit CEO Excellence Award, GlaxoSmithKline the psychiatry CEDD Leadership Team Award. He is also on the editorial board for several journals. He has published over 33 research articles related to drug metabolism, in vivo-in vitro correlation, drug-drug interaction, HPLC, NMR and mass spectrometry.
E. Kantharaj R & D Technical, D3, A*STAR Singapore Biography
Biography of E. Kantharaj
Ethirajulu Kantharaj currently works at D3, A*STAR, Singapore as Head of Technical, R & D. He is a professional drug discovery & development leader with 21 years of experience in DMPK, CMC and Toxicology and early drug development across therapy areas in both small biotech and large pharmaceutical setting. In D3, he is responsible for all the preclinical development activities starting from preclinical development candidate to IND submissions. He was involved in the preclinical development of several NMEs leading to successful INDs in USA and regulatory submissions in Singapore and Australia enabling start of clinical studies. He also strategized successful regulatory meetings with both US (FDA) and EU (EMA) for seeking agreements on the non-clinical development plans and strategy from pre-IND stages to advanced clinical development stages. Previously, Dr Ethirajulu has worked with S*BIO Pte Ltd, Johnson & Johnson Pharmaceutical Research and Development as team leader, ADME/Tox department and AstraZeneca R&D as Head of DMPK and Bioanalytical Chemistry.
S. Kar Jackson State University Jackson, MS USA Biography
Biography of S. Kar
Dr. Supratik Kar is a research associate at Jackson State University, Mississippi, USA. He has completed his B. Pharm. (2008) and M. Pharm. (2010) degree from Jadavpur University (Kolkata, India) securing first position in both degrees and earned his PhD (2015) from the Jadavpur University (Kolkata, India). Former visiting researcher at the University of Gdańsk (Poland). Has experience in molecular modeling studies for ten years. He has published 50 research and review articles, 9 book chapters till date with h-index 20. He has also coauthored 2 QSAR related books in Academic press and Springer. Reviewer of more than 15 reputed journals. ORCID: orcid.org/0000-0002-9411-2091.
J. Lampe The University of Kansas Medical Center Kansas City, KS USA Biography
Biography of J. Lampe
Dr. Jed Lampe is an R01-funded principal investigator, educator, and scientific leader in the
ADME/DMPK field. After receiving his Ph.D. in Medicinal Chemistry from the University of Washington,
he completed post-doctoral training at UCSF under the tutelage of Professor Paul Ortiz de Montellano,
where he studied ligand binding dynamics and their relationship to enzyme function in cytochrome P450
enzymes using pioneering 2-dimensional NMR techniques with site-specifically incorporated unnatural
amino acids. More recently, he has served as an Assistant Professor in the Department of Pharmacology,
Toxicology and Therapeutics at the University of Kansas Medical Center where his current research
interests involve the application of bioanalytical, biophysical, and computational techniques to
understand and predict drug metabolism and disposition in the neonate and developing infant. He
serves on a number of editorial boards, including Current Drug Metabolism, PLOS One, and the Journal
of Drug Metabolism and Toxicology.
Su.-J. Lee Inje University Busan South Korea Biography
Biography of Su.-J. Lee
Dr. Su-Jun Lee received his PhD degree in Toxicology from Oregon State University, USA and finished his post-doctoral research fellow in NIH, USA. Dr. Su-Jun Lee has been professor of Department of Pharmacology at Inje University College of Medicine, Inje University, Korea since 2006. He has authored over 50 publications and several book chapters. He has been serving as a reviewer and an editorial board member for a number of journals. His research interest includes pharmacogenomics, functional genomics, drug metabolism, and molecular toxicology.
C. Liu Tianjin Institute of Pharmaceutical Research Tianjin China Biography
Biography of C. Liu
Professor Chang-Xiao Liu graduated from Peking University School of Pharmaceutical Sciences (formerly Beijing Medical College) in 1965. In research career of 50 years, Liu has been committed to the study of drug metabolism/pharmacokinetics and pharmacology, and has particularly outstanding contributions on innovative drugs and compound Chinese medicine formulations. Professor Liu published more than 300 academic articles and 12 books on drug metabolism and pharmacokinetics in English and in Chinese. Now Liu served as a Director of State Key Laboratory of drug delivery technology pharmacokinetics and ISSX China Office. Liu won the Bauhinia Medical Achievement Award (Hong Kong) in 2000, elected Academician of Chinese Academy of Engineering in 2003 and was awarded the Special Contribution Award ISSX in 2013.
Dr. Yi Lu received his Ph.D. in Pharmaceutics from Sichuan University in 2006 and joined
Fudan University after graduation. In 2011, he was promoted to be an associate
professor. Dr. Lu’s research interests include nano-drug delivery systems, transdermal
drug delivery systems and nanocrystals. Recently, he developed self-discriminative
hybrid nanocrystals with ACQ fluorescent probes to explore in vivo fate of nanocrystals.
He has published more than 90 peer-reviewed articles in SCI journals, five book
chapters, and has applied for seven patents. Dr. Lu is also editorial board member of
Journal of Basic and Clinical Pharmacy and Chinese Chemical Letters.
C. Prakash CP Pharma Consulting Principal, Drug Metabolism and Pharmacokinetics Cambridge, MA USA Biography
Biography of C. Prakash
Dr. Prakash is a Senior Research Fellow in Drug Metabolism, Pharmacokinetics and Clinical Pharmacology department at Agios, Cambridge, MA. Prior to joining Agios, he worked at Vanderbilt University, Pfizer Global Research and Development and Bogen. For the last 30 years, Dr. Prakash has been involved in the drug metabolism and clinical pharmacology studies to support drug discovery, development and registration. His research is primarily focused on the development and utilization of novel approaches and techniques to assess the metabolism and toxicological aspects of the new chemical entities. He is the author of more than 265 manuscripts, book chapters, presentations and patents.
J.F. Rusling University of Connecticut Storrs, CT USA Biography
Biography of J.F. Rusling
James F. Rusling was awarded the B.Sc. in Chemistry from Drexel University in 1969, and Ph. D. from Clarkson University in 1979. He is Professor of Chemistry at University of Connecticut, Professor of Surgery and member of the Neag Cancer Center at University of Connecticut Health Center, and adjunct Professor of Chemistry at National Univ. of Ireland. Galway. Current research includes new cancer diagnostics via detection of biomarker proteins, low-cost 3D printed immunoarrays for point-of-care diagnostics, electrochemical and mass spectrometric arrays for toxicity screening, tumor suppressor gene damage, and fundamental bioelectrochemistry. He has authored more than 380 research papers and several books, and is a musician interested in Irish and American folk styles.
A.C. Silva University of Porto and Fernando Pessoa University Porto Portugal Biography
Biography of A.C. Silva
Assistant Professor of Pharmaceutical Technology and Biotechnology. Researcher at CEBIMED, FP-ENAS, University Fernando Pessoa, Porto, Portugal. Invited Professor and Researcher at UCIBIO, ReQuimTe, Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Portugal.
European PhD in Pharmaceutical Sciences (specialization in Pharmaceutical Technology), University of Porto. Graduation in Pharmaceutical Sciences, University Fernando Pessoa. Current research interests: development of new delivery systems for oral, cutaneous and nasal administration of drugs and biopharmaceuticals. Author and reviewer for several international scientific journals in the area of Pharmaceutical Technology and Biotechnology. Supervisor and co-supervisor of PhD, MSc and Undergraduate students.
M. Soars Bristol-Myers Squibb Wallingford, CT USA Biography
Biography of M. Soars
Dr Soars is a Senior Principal Scientist in the Metabolism and Pharmacokinetics department at Bristol-Myers Squibb in Wallingford CT. He received his Bachelors in biochemistry from the University of Warwick in 1998 and a Phd from the University of Dundee in 2002. From 2002-2003, he completed a postdoctoral fellowship at Eli Lilly where he worked on drug glucuronidation under the supervision of Steve Wrighton. He then moved to AstraZeneca where he worked for 8 years developing and implementing both drug metabolism assays and more recently transporter methodology. Since 2011 Dr. Soars has worked at Bristol –Myers Squibb where he helped develop the transporter strategy in Drug Discovery. Research interests include the prediction of pharmacokinetics and drug-drug interactions for new chemical entities and also the application of drug transporter methodology in early Drug Discovery. Dr Soars has published more than 30 scientific publications and is on the Editorial advisory board for a number of publications including Xenobiotica, Current Drug Metabolism and Drug Metabolism letters.
B.L. Tekwani University of Mississippi Oxford, MS USA
Y. Uesawa Meiji Pharmaceutical University Tokyo Japan Biography
Biography of Y. Uesawa
Yoshihiro Uesawa received his Ph.D. degree from the Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan, in 1992. He is a Professor at Meiji Pharmaceutical University, Tokyo, Japan. His major areas of research are related to computational toxicology, pharmaceutical interactions between medications and foods, analyses of quantitative structure-activity relationships (QSAR), machine learning, and data mining. In September of 2009, he became a first-pass winner in the CADASTER Environmental Toxicity Prediction Challenge, organized by ICANN’09: International Conference on Artificial Neural Networks, European Neural Network Society and CADASTER project. In addition, in January 2015, he became one of the winners in the “Tox21 DATA Challenge 2014”, organized by NIH, USA.
M. Ulgen Acibadem University Istanbul Turkey Biography
Biography of M. Ulgen
Prof. Dr. Mert Ulgen graduated from Marmara University, Faculty of Pharmacy, Istanbul, Turkey in 1981. He finished his MSc degree at the same department and in 1992, he obtained a PhD degree from University of London, King's College, Biopharmacy Department in the area of Drug Metabolism. He returned to Turkey and became an associated Professor in 1993 and a full professor in 1999 at the same department in the area of Pharmaceutical Chemistry. He has got a number of papers on drug synthesis and in vitro hepatic microsomal metabolism of xenobiotics. He directed a number of MSc and PhD thesis. He retired from Marmara University in June 2009 and he became a full time Professor at Acıbadem University, Vocational School of Health Services in the same year. He has a number of administrative duties. He is also a full time chemistry lecturer. He was Director of Enstitute of Health Sciences in Acıbadem University one term (2013-2016). He established Faculty of Pharmacy at the same University in early 2016 and he is currently dean of Pharmacy. He is also head of "Management in Drug Industry" MSc Program.
H. Wang University of Maryland School of Pharmacy Baltimore, MD USA Biography
Biography of H. Wang
Dr. Hongbing Wang, Professor & Program Chair, Experimental and Translational
Therapeutics, Department of Pharmaceutical Sciences, University of Maryland
School of Pharmacy. Dr. Wang’s research interests including investigation of the
molecular mechanisms that govern nuclear receptor‐mediated induction of
metabolizing enzymes and drug transporters in humans, metabolism‐based drugdrug
interactions, and drug‐induced liver toxicity.
Dr. Baojian Wu is a Professor of Biopharmaceutics at Jinan University, Guangzhou, China. He is the receiver of “863 Program Young Scientist” and “the Nature Science Foundation of Guangdong for Outstanding Young Scientist”. His primary research interests are the disposition processes and metabolic regulation of phenolic active compounds derived from traditional Chinese medicines (TCM). Dr. Wu’s group has discovered that efflux transporters (MRPs and BCRP) mediated the excretion transport of phase II metabolites, and surprisingly regulated cellular metabolism of phenolic compounds. He has obtained nine research grants and published over 90 papers in SCI journals such as Biochem Pharmacol, Mol Pharm, Pharm Res and Drug Metab Dispos. Dr. Wu received his Ph.D. at the University of Houston, and completed post-doctoral training at Balor College of Medicine. He is serving on the editorial board for two scientific journals, Xenobiotica and Curr Drug Metab.
J. Xiao Institute of Bast Fiber Crops Changsha China Biography
Biography of J. Xiao
Prof. Jianbo Xiao obtained his Ph.D. degree in nutritional science from Okayama Prefectural University, Japan, in 2009. Prof. Xiao worked at University of Wuerzbug, Germany from 2013 to 2015, prior to joining University of Macau, China, in 2015. His research interests include nutrition and metabolism of polyphenols, stability of polyphenols, and polyphenols & diabetes. Prof. Xiao has published over 180 papers in international journals. He was a chairperson of 2015 International Symposium on Phytochemicals in Medicine and Food (1-ISPMF 2015) organized by PSE, its second edition (2-ISPMF 2017), and its third edition (3-ISPMF 2018).
J. Xie Tianjin University of Traditional Chinese Medicine Tianjin China Biography
Biography of J. Xie
Dr. Xie is currently a professor of Tianjin University of Traditional Chinese Medicine. His research mainly covers the metabolism, pharmacokinetics and molecular mechanisms of drug (especially herbal bioactive components, including polysaccharide, saponis, flavonoids, et al). In addition, he also focused on the development of new techniques (such as biosensors) for evaluating the safty and bioactivity of the drug. He has published more than 100 scientific publications and is currently an editor of this journal.
H. Yamazaki Showa Pharma University Tokyo Japan Biography
Biography of H. Yamazaki
Dr. Hiroshi Yamazaki has been Professor of Laboratory of Drug Metabolism and Pharmacokinetics at Showa Pharmaceutical University, Tokyo, Japan since 2005. He received his PhD degree from Osaka University in Japan and was trained at Vanderbilt University, TN, USA in 1994. He was a scientist at Osaka Prefectural Institute of Public Health and an Associate Professor of Kanazawa (1998) and Hokkaido (2001) University. He has authored over 340 publications and has been the recipient of the Japanese Society for the Study of Xenobiotics (JSSX) Award and Fellow. He is a member of several editorial committees and the JSSX President-elect (2016-2017).
H-P. Yu Chang Gung Memorial Hospital Taoyuan Taiwan Biography
Biography of H-P. Yu
Professor Huang-Ping Yu, MD, PhD, works as the Professor and Chairman of Department of Anesthesiology and Vice Chairman of Committee of Medical Research Evaluation of Chang Gung Medical Center (around 3,700 ward beds). In addition, Professor Yu is appointed as the member of Editorial Board of international ‘SHOCK’ journal and associate Editor of Asian Journal of Anesthesiology. He has over 110 publications of book chapters, original articles and review papers being published in the English peer review journals. Professor Yu’s studies investigating the mechanism of therapeutic reagents-induced improvement of organ function and the potential use of therapeutic reagents after trauma/sepsis to prevent organ dysfunction, therefore represent a novel and innovative approach for maintaining organ function under those conditions.
B.N.M. Zordoky University of Minnesota Minneapolis, MN USA Biography
Biography of B.N.M. Zordoky
Dr. Beshay Zordoky has completed his PhD in pharmaceutical sciences and his postdoctoral training in cardiovascular research from University of Alberta, Canada. He is currently an assistant professor in the department of Experimental and Clinical Pharmacology, University of Minnesota, USA. He has published 31 papers, one book chapter, and more than 35 abstracts (h-index of 21). He has been serving as a reviewer and an editorial board member of a number of reputable journals. His research interests include cardio-oncology, cardiovascular pharmacology, and drug metabolism.
Michael Sinz Bristol Myers Squibb Princeton, NJ USA